PL367632A1 - Nowe krystaliczne formy kwasu 4-[4-[4-(hydroksy-difenylometylo)-1-piperyndynylo]-1-hydroksybutylo]-, -dimetylobenzenooctowego i jego chlorowodorku - Google Patents

Nowe krystaliczne formy kwasu 4-[4-[4-(hydroksy-difenylometylo)-1-piperyndynylo]-1-hydroksybutylo]-, -dimetylobenzenooctowego i jego chlorowodorku

Info

Publication number
PL367632A1
PL367632A1 PL01367632A PL36763201A PL367632A1 PL 367632 A1 PL367632 A1 PL 367632A1 PL 01367632 A PL01367632 A PL 01367632A PL 36763201 A PL36763201 A PL 36763201A PL 367632 A1 PL367632 A1 PL 367632A1
Authority
PL
Poland
Prior art keywords
piperindinyl
hydroxydiphenylmethyl
hydroxybutyl
hydrochloride
acetic acid
Prior art date
Application number
PL01367632A
Other languages
English (en)
Inventor
S.Thirumalai Rajan
U.V.Bhaskara Rao
M.Satyanarayana Reddy
Original Assignee
Dr.Reddy's Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr.Reddy's Laboratories Limited filed Critical Dr.Reddy's Laboratories Limited
Publication of PL367632A1 publication Critical patent/PL367632A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL01367632A 2001-06-18 2001-07-31 Nowe krystaliczne formy kwasu 4-[4-[4-(hydroksy-difenylometylo)-1-piperyndynylo]-1-hydroksybutylo]-, -dimetylobenzenooctowego i jego chlorowodorku PL367632A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN484MA2001 2001-06-18
PCT/US2001/023994 WO2002102777A2 (en) 2001-06-18 2001-07-31 NOVEL CRYSTALLINE FORMS OF 4-[4-[4-(HYDROXYDIPHENYLMETHYL)-1-PIPERINDINYL]-1-HYDROXYBUTYL]-α, α-DIMETHYLBENZENE ACETIC ACID AND ITS HYDROCHLORIDE

Publications (1)

Publication Number Publication Date
PL367632A1 true PL367632A1 (pl) 2005-03-07

Family

ID=34566868

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01367632A PL367632A1 (pl) 2001-06-18 2001-07-31 Nowe krystaliczne formy kwasu 4-[4-[4-(hydroksy-difenylometylo)-1-piperyndynylo]-1-hydroksybutylo]-, -dimetylobenzenooctowego i jego chlorowodorku

Country Status (20)

Country Link
EP (2) EP2261209A1 (pl)
JP (2) JP2005507374A (pl)
KR (1) KR20040015734A (pl)
CN (1) CN100390145C (pl)
AU (1) AU2001278094B2 (pl)
BG (1) BG108435A (pl)
BR (1) BR0117054A (pl)
CA (2) CA2646802A1 (pl)
CO (1) CO5540340A2 (pl)
CZ (1) CZ20033358A3 (pl)
EE (1) EE200400010A (pl)
HU (1) HUP0401546A2 (pl)
IL (2) IL159266A0 (pl)
MX (1) MXPA03011728A (pl)
NZ (1) NZ530118A (pl)
PL (1) PL367632A1 (pl)
RU (1) RU2269516C2 (pl)
SK (1) SK15372003A3 (pl)
WO (1) WO2002102777A2 (pl)
ZA (1) ZA200309557B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
EP1474392A1 (en) 2002-06-10 2004-11-10 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
GB0319935D0 (en) 2003-08-26 2003-09-24 Cipla Ltd Polymorphs
WO2005102999A2 (en) * 2004-04-26 2005-11-03 Teva Pharmaceutical Industries Ltd. Crystalline forms of fexofenadine hydrochloride and processes for their preparation
ITMI20041143A1 (it) * 2004-06-08 2004-09-08 Dipharma Spa Polimorfi di fexofenadina e procedimento per la loro preparazione
ITMI20041568A1 (it) * 2004-07-30 2004-10-30 Dipharma Spa "polimorfi di fexofenadina base"
WO2006037042A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
WO2007007347A1 (en) * 2005-07-07 2007-01-18 Wockhardt Limited Industrial process of fexofenadine hydrochloride with controlled side products
EP2105134A1 (en) 2008-03-24 2009-09-30 Ranbaxy Laboratories Limited Stable amorphous fexofenadine hydrochloride
CN104072402B (zh) * 2014-07-16 2016-08-17 昆山龙灯瑞迪制药有限公司 一种新结晶形式的盐酸非索非那定化合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
WO1995031437A1 (en) * 1994-05-18 1995-11-23 Hoechst Marrion Roussel, Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
US6153754A (en) * 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
IN191492B (pl) 1999-05-25 2003-12-06 Ranbaxy Lab Ltd
GB0018691D0 (en) * 2000-07-28 2000-09-20 Rolabo Sl Process

Also Published As

Publication number Publication date
CZ20033358A3 (en) 2004-04-14
BR0117054A (pt) 2004-07-27
JP2005507374A (ja) 2005-03-17
WO2002102777A3 (en) 2003-02-27
IL159266A0 (en) 2004-06-01
CN100390145C (zh) 2008-05-28
CA2450858A1 (en) 2002-12-27
ZA200309557B (en) 2004-09-14
WO2002102777A8 (en) 2003-10-30
AU2001278094B2 (en) 2006-01-12
EP2261209A1 (en) 2010-12-15
EP1399422A2 (en) 2004-03-24
CA2646802A1 (en) 2002-12-27
BG108435A (en) 2004-12-30
HUP0401546A2 (hu) 2004-12-28
CN1518540A (zh) 2004-08-04
CA2450858C (en) 2009-04-07
RU2004101045A (ru) 2005-06-27
KR20040015734A (ko) 2004-02-19
RU2269516C2 (ru) 2006-02-10
CO5540340A2 (es) 2005-07-29
MXPA03011728A (es) 2004-07-08
JP2008094848A (ja) 2008-04-24
IL159266A (en) 2010-11-30
EE200400010A (et) 2004-02-16
NZ530118A (en) 2007-05-31
SK15372003A3 (sk) 2004-08-03
WO2002102777A2 (en) 2002-12-27

Similar Documents

Publication Publication Date Title
PL367632A1 (pl) Nowe krystaliczne formy kwasu 4-[4-[4-(hydroksy-difenylometylo)-1-piperyndynylo]-1-hydroksybutylo]-, -dimetylobenzenooctowego i jego chlorowodorku
EE200400019A (et) 1-[4-(5-tsüanoindool-3-üül)butüül]-4-(2-karbamoüülbensofuraan-5-üül)piperasiinvesin ikkloriidi polümorfsed vormid
IL146707A0 (en) Novel use of 1-[4-(5-cyanoindol-3-yl) butyl]-4-(2-carbamoyl-benzofuran-5-yl)- piperazine and its physiologically acceptable salts
NO20000115L (no) Gastrokinetiske monocykliske benzamidler av 3- eller 4- substituerte 4-(aminometyl)-piperidinderivater
AU2002360561A1 (en) 4-substituted piperidines, and methods of use thereof
IS7271A (is) Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines
WO2001094313A3 (en) Crystal modification of fexofenadine
EP1465601A4 (en) STABLE PHARMACEUTICAL FORMULATION OF PAROXETINE ANHYDROUS HYDROCHLORIDE AND PREPARATION METHOD
PL325264A1 (en) Novel derivatives of phenyl-alpha,alpha-dimethylacetic acid, method of obtaining such derivatives, method of obtaining a pharmaceutic agent, application of such derivatives and method of obtaining 4-{4-[4-(hydroxydiphenylmethyl)piperidin]-1-hydroxybutyl}-phenyl-alpha,alpha-dimethylacetic acid
HUP0201673A3 (en) Process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-alpha, alpha-dimethylbenzeneacetic acid
DK1531151T3 (da) Fremgangsmåde til fremstilling af 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidin, hydrochlorid
NZ306319A (en) 1-alkylphenyl substituted 4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butanol derivatives and medicaments
WO2002100847A3 (en) Factor xa inhibitor
NO20040479L (no) Solvater av lerkanidipinhydroklorid og nye krystallinske former av lerkanidipinhydroklorid.
IL152570A0 (en) A process for the preparation of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-alpha, alpha-di methylbenzeneacetic acid
YU61503A (sh) Nova so benzoilgvanidina
IL161521A0 (en) N-formyl derivatives of paroxetine
HK1062683A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(E)-=-methyloxime and its salts.
NO20042946L (no) Piperidin-2,6-dioner som er heterocyklisk substituert i posisjon 3
MXPA01005769A (es) Nuevas formas cristalinas del acido (3s-trans) -2[3,4-dihidro -4-hidroxi -3-(enilmetil)-2h -1-benzofiran -7-il] -4- (trifluorometil) benzoico.
CA2188507A1 (en) Crystals of piperidine derivatives, intermediates for production of the same, and process for producing the same
AU2002359274A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
AU2003300259A1 (en) Crystalline 2- `(2-aminoethoxy) methyl!-4-(2-chlorophenyl) -3-ethoxycarbonyl-5-methoxycarbonyl-6- methyl-1, 4-dihydropyridine maleate salt (amplodipine)
SI1436282T1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
ZA986167B (en) Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)